$TVGN $MSFT

Tevogen Bio announces AI collaboration with Microsoft

Tevogen Bio Holdings Inc. (TVGN) announced that it has broadened its relationship with Microsoft (MSFT) to broaden its AI-focused collaboration and build its PredicTcell technology. 

PredicTcell is Tevogen Bio's proprietary technology designed for predictive precision T cell targeting. This expanded relationship is designed to harness Microsoft's cutting-edge AI, cloud capabilities, and Microsoft's health and life sciences domain expertise to accelerate Tevogen Bio's target identification and pre-clinical processes, strengthening the company's pipeline of innovative immunotherapies.Tevogen Bio's artificial intelligence effort, will integrate Microsoft's advanced AI tools and the Microsoft Azure cloud platform into two key objectives: Building on the successful trial results of TVGN 489, Tevogen Bio aims to utilize machine learning to perform critical simulations that will accelerate the identification of new targets. By leveraging Microsoft's AI, the company can analyze large datasets across the genome with greater speed and accuracy. 

Also,in collaboration with Microsoft domain experts, will create new algorithms to decode the interactions between human leukocyte antigens and T cells. This capability is expected to significantly enhance Tevogen Bio's understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data. "As we expand our AI efforts, this broader relationship with Microsoft represents a key milestone in our ongoing journey to revolutionize immunotherapy," said Mittul Mehta, CIO of Tevogen Bio and Head of"Through deeper collaboration with Microsoft domain experts, we will further harness the power of AI to bring more precise and personalized treatments to patients at an accelerated pace."
#TVGN #MSFT